SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

详细信息    查看全文

• 作者：Ram贸n De las Pe帽as ; Santiago Ponce ; Fernando Henao…
• 关键词：Antidiuretic hormone receptor antagonists ; Day care units ; Hyponatremia ; Inappropriate ADH syndrome ; Tolvaptan
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：24
• 期：1
• 页码：499-507
• 全文大小：824 KB
• 参考文献：1.Verbalis JG, Adler S, Schrier RW, for the SALT Investigators et al (2011) Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 164:725鈥?32PubMedCentral CrossRef PubMed
  2.Alc谩zar R, Puerta M (2013) SIADH: Pathophysiology, classification and diagnosis in the hospitalized patient. FMC: Oncolog铆a 8: supl 1
  3.Runkle I, Villabona C, Navarro A et al (2014) Tratamiento de la hiponatremia secundaria al syndrome de secreci贸n inadecuada de la hormona antidiur茅tica: algoritmo multidisciplinar. Nefrol 4:439鈥?50
  4.S酶rensen JB, Andersen MK, Hansen HH (1995) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238:97鈥?10CrossRef PubMed
  5.Gill G, Huda B, Boyd A et al (2006) Characteristics and mortality of severe hyponatraemia: a hospital based study. Clin Endocrinol 65:246鈥?49CrossRef
  6.Sherlock M, O鈥橲ullivan E, Agha A et al (2006) The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol 64:250鈥?54CrossRef
  7.Sherlock M, O鈥橲ullivan E, Agha A et al (2009) Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J 85:171鈥?75CrossRef PubMed
  8.Shea AM, Hammill BG, Curtis LH et al (2008) Medical costs of abnormal serum sodium levels. J A Soc Nephrol 19:764鈥?70CrossRef
  9.Samsca (2014) Summary of product characteristics
  10.De las Pe帽as R, Escobar Y, Henao F et al (2014) SEOM guidelines on hydroelectrolitic disorders. Clin Transl Oncol. doi:10.鈥?007/鈥媠12094-014-1234-2 PubMedCentral
  11.Castillo JJ, Vicent M, Justice E (2012) Diagnosis and management of hyponatremia in cancer patients. Oncologist 17:756鈥?65PubMedCentral CrossRef PubMed
  12.Ellison DH, Berl T (2007) The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064鈥?072CrossRef PubMed
  13.De las Pe帽as R (2013) Syndrome of inappropriate antidiuretic hormone secretion in the hospitalized oncologic patient. FMC: Oncolog铆a 8: supl 1
  14.Schrier RW, Bansal S (2008) Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care 14:627鈥?34PubMedCentral CrossRef PubMed
  15.Adrogue HJ, Madias NE (2000) Hyponatremia. N Eng J Med 342:1581鈥?589CrossRef
  16.Verbalis JG, Goldsmith SR, Greenberg A et al (2013) Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 126:S1鈥揝42CrossRef PubMed
  17.Hannon MJ, Thompson CJ (2010) The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol 162:S5鈥揝12CrossRef PubMed
  18.Groh茅 C, et al. Hyponatraemia-SIADH in lung cancer diagnostic and treatment algorithms. Crit Rev Oncol Hematol. 2015 Apr 23. doi: 10.鈥?016/鈥媕.鈥媍ritrevonc.鈥?015.鈥?4.鈥?05
  19.Gankam-Kengne F, Ayers C, Khera A et al (2013) Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. Kid Int 83:700鈥?06CrossRef
  20.Hansen O, Sorensen P, Hansen KH (2010) The occurrence of hyponatremia in SCLC and the influence on prognosis. A retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68:111鈥?14CrossRef PubMed
  21.Berardi R, Caramanti M, Castagnani M et al. (2015) Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer. Mar 5
  22.Berardi R, Caramanti M, Fiordoliva I et al (2015) Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer 23:621鈥?26CrossRef PubMed
  23.Waikar SS, Mount DB, Curhan GC et al (2009) Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 122:857鈥?65PubMedCentral CrossRef PubMed
  24.Doshi SM, Shah P, Lei X et al (2012) Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 59:222鈥?28CrossRef PubMed
  25.Wald R, Jaber BL, Price LL et al (2010) Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 170:294鈥?02CrossRef PubMed
  26.Arraras JI, Illarramendi JJ, Viudez A et al (2013) Determinants of patient satisfaction with care in a Spanish oncology day hospital and its relationship with quality of life. Psycho-Oncology 22:2454鈥?461CrossRef PubMed
  27.Sengupta A, Banerjee SN, Biswas NM et al (2013) The incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patients. J Clin Diagn Res 7:1678鈥?682PubMedCentral PubMed
  28.Callahan MA (2009) Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med 121:186鈥?91CrossRef PubMed
  29.Sheea AM, Hammill BG, Curtis LH et al (2008) Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 19:764鈥?70CrossRef
  30.Boscoe A, Paramore C, Verbalis JG et al (2006) Cost of illness of hyponatremia in the United States. Effect Resour All 4:10CrossRef
  31.Runkle I, G贸mez-Hoyos E, Cuesta-Hern谩ndez M et al (2015) Hyponatraemia in older patients: a clinical and practical approach. Rev Clin Gerontol 25:31鈥?2CrossRef
  
• 作者单位：Ram贸n De las Pe帽as (1)
  Santiago Ponce (2)
  Fernando Henao (3)
  Carlos Camps Herrero (4)
  Enric Carcereny (5)
  Yolanda Escobar 脕lvarez (6)
  C茅sar A. Rodr铆guez (7)
  Juan Antonio Virizuela (3)
  Rafael L贸pez L贸pez (8)
  
  1. Medical Oncology Department, Consorcio Hospitalario Provincial de Castell贸n, Castell贸n, Spain
  2. Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain
  3. Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain
  4. Medical Oncology Department, Consorcio Hospital General Universitario de Valencia, University of Valencia, Valencia, Spain
  5. Medical Oncology Department, Institut Catal脿d鈥橭ncologia-Badalona, Hospital Germans Trias i Pujol, Barcelona, Spain
  6. Medical Oncology Service, Hospital General Universitario Gregorio Mara帽贸n, Madrid, Spain
  7. Medical Oncology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
  8. Medical Oncology Department, Hospital Cl铆nico Universitario, Santiago de Compostela, Spain
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Hyponatremia (Na 藗135 mmol/l) is the most frequent electrolyte disorder in clinical practice, and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the commonest cause of hyponatremia in cancer patients. Correcting hyponatremia in these patients can reduce morbidity and mortality, increase the response to anti-cancer agents, and help reduce hospital length of stay and costs. Tolvaptan is an oral medication used to treat SIADH-related hyponatremia patients that needs to be initiated at hospital so patients can have their serum sodium monitored. If tolvaptan could be initiated in hospital day care units (DCUs), performing the same tests, hospitalization could be avoided, quality of life improved, and costs reduced. This is the first publication where a panel of oncologists are sharing their experience and making some recommendations with the use of tolvaptan to treat SIADH-related hyponatremia in DCU after collecting and examining 35 clinical cases with these type of patients. The conclusion from this retrospective observational analysis is that the use of tolvaptan in DCU is safe and effective in the therapeutic management of SIADH-related hyponatremia. Keywords Antidiuretic hormone receptor antagonists Day care units Hyponatremia Inappropriate ADH syndrome Tolvaptan